Statement of Changes in Beneficial Ownership (4)
October 12 2021 - 04:35PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5
obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL
OWNERSHIP OF SECURITIES
|
OMB
APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5 |
|
Filed pursuant to Section 16(a) of the
Securities Exchange Act of 1934 or Section 30(h) of the Investment
Company Act of 1940
|
|
1. Name
and Address of Reporting Person * MPM BIOVENTURES 2018,
L.P. |
2. Issuer Name and Ticker or Trading
Symbol iTeos Therapeutics, Inc. [ ITOS ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)_____
Director __X__
10% Owner
_____ Officer (give title
below) _____ Other
(specify below)
|
(Last)
(First)
(Middle)
C/O MPM CAPITAL, 450 KENDALL STREET |
3. Date of Earliest Transaction (MM/DD/YYYY)
10/7/2021
|
(Street)
CAMBRIDGE, MA 02142
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line) ___
Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting
Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or
Beneficially Owned
|
1.Title of Security
(Instr. 3) |
2. Trans. Date |
2A. Deemed Execution Date, if any |
3. Trans. Code
(Instr. 8) |
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following
Reported Transaction(s)
(Instr. 3 and 4) |
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4) |
7. Nature of Indirect Beneficial Ownership (Instr.
4) |
Code |
V |
Amount |
(A) or (D) |
Price |
Common Stock |
10/7/2021 |
|
S(1) |
|
1149 (2) |
D |
$27.00 (3) |
3259704 |
I |
See Footnote (4) |
Common Stock |
10/8/2021 |
|
S(1) |
|
2032 (5) |
D |
$27.01 (6) |
3257672 |
I |
See Footnote (7) |
Common Stock |
10/11/2021 |
|
S(1) |
|
48812 (8) |
D |
$27.24 (9) |
3208860 |
I |
See Footnote (10) |
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible
securities)
|
1. Title of Derivate Security
(Instr. 3) |
2. Conversion or Exercise Price of Derivative
Security |
3. Trans. Date |
3A. Deemed Execution Date, if any |
4. Trans. Code
(Instr. 8) |
5. Number of Derivative Securities Acquired (A) or
Disposed of (D)
(Instr. 3, 4 and 5) |
6. Date Exercisable and Expiration Date |
7. Title and Amount of Securities Underlying
Derivative Security
(Instr. 3 and 4) |
8. Price of Derivative Security
(Instr. 5) |
9. Number of derivative Securities Beneficially
Owned Following Reported Transaction(s) (Instr. 4) |
10. Ownership Form of Derivative Security: Direct
(D) or Indirect (I) (Instr. 4) |
11. Nature of Indirect Beneficial Ownership (Instr.
4) |
Code |
V |
(A) |
(D) |
Date Exercisable |
Expiration Date |
Title |
Amount or Number of Shares |
Explanation of
Responses: |
(1) |
Transaction effected
pursuant to a plan established pursuant to Rule 10b5-1. |
(2) |
The shares were sold as
follows: 684 by MPM BioVentures 2014, L.P. ("BV 2014"), 24 by MPM
Asset Management Investors BV2014 LLC ("AM BV2014"), 432 by MPM
BioVentures 2018, L.P. ("BV 2018") and 9 by MPM Asset Management
Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and
MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and
indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is
the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM
BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect
general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the
manager of AM BV2018. Messrs. Evnin and Foley are managing
directors of BV 2014 LLC and BV 2018 LLC. |
(3) |
The price reported in Column
4 is a weighted average price. These shares were sold in multiple
transactions at prices ranging from $26.95 to $27.07 inclusive. The
Reporting Person undertakes to provide to the Issuer, any security
holder of the Issuer, or the staff of the Securities and Exchange
Commission, upon request, full information regarding the number of
shares sold at each separate price within the range set forth in
this footnote. |
(4) |
The shares are held as
follows: 1,845,606 ,by BV 2014, 107,713 by MPM BioVentures 2014(B),
L.P. ("BV 2014(B)"), 63,523 by AM BV2014, 1,165,645 by BV 2018,
54,213 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)") and 23,004
by AM BV2018. The Reporting Person disclaims beneficial ownership
of the securities except to the extent of his or its respective
pecuniary interest therein. |
(5) |
The shares were sold as
follows: 1,210 by BV 2014, 42 by AM BV2014, 765 by BV 2018 and 15
by AM BV2018. |
(6) |
The price reported in Column
4 is a weighted average price. These shares were sold in multiple
transactions at prices ranging from $26.97 to $27.035 inclusive.
The Reporting Person undertakes to provide to the Issuer, any
security holder of the Issuer, or the staff of the Securities and
Exchange Commission, upon request, full information regarding the
number of shares sold at each separate price within the range set
forth in this footnote. |
(7) |
The shares are held as
follows: 1,844,396 by BV 2014, 107,713 by BV 2014(B), 63,481 by AM
BV2014, 1,164,880 by BV 2018, 54,213 by BV 2018(B) and 22,989 by AM
BV2018. Each of the Reporting Persons disclaims beneficial
ownership of the securities herein except to the extent of his or
its respective pecuniary interest therein, if any. |
(8) |
The shares were sold as
follows: 29,081 by BV 2014, 1,001 by AM BV2014, 18,367 by BV 2018
and 363 by AM BV2018. |
(9) |
The price reported in Column
4 is a weighted average price. These shares were sold in multiple
transactions at prices ranging from $26.95 to $27.53 inclusive. The
Reporting Person undertakes to provide to the Issuer, any security
holder of the Issuer, or the staff of the Securities and Exchange
Commission, upon request, full information regarding the number of
shares sold at each separate price within the range set forth in
this footnote. |
(10) |
The shares are held as
follows: 1,815,315 by BV 2014, 107,713 by BV 2014(B), 62,480 by AM
BV2014, 1,146,513 by BV 2018, 54,213 by BV 2018(B) and 22,626 by AM
BV2018. The Reporting Person disclaims beneficial ownership of the
securities except to the extent of his or its respective pecuniary
interest therein. |
Remarks:
See Form 4 for MPM BioVentures 2014, L.P for additional members of
this joint filing. |
Reporting
Owners
|
Reporting Owner Name / Address |
Relationships
|
Director |
10% Owner |
Officer |
Other |
MPM BIOVENTURES 2018, L.P.
C/O MPM CAPITAL
450 KENDALL STREET
CAMBRIDGE, MA 02142 |
|
X |
|
|
MPM BioVentures 2018 LLC
C/O MPM CAPITAL
450 KENDALL STREET
CAMBRIDGE, MA 02142 |
|
X |
|
|
MPM BioVentures 2018 GP LLC
C/O MPM CAPITAL
450 KENDALL STREET
CAMBRIDGE, MA 02142 |
|
X |
|
|
Signatures
|
/s/ Ansbert Gadicke, managing director of MPM
BioVentures 2018 LLC, the managing member of MPM BioVentures 2018
GP LLC, the general partner of MPM BioVentures 2018,
L.P. |
|
10/12/2021 |
**Signature of Reporting
Person |
Date |
/s/ Ansbert Gadicke, managing director of MPM
BioVentures 2018 LLC |
|
10/12/2021 |
**Signature of Reporting
Person |
Date |
/s/ Ansbert Gadicke, managing director of MPM
BioVentures 2018 LLC, the managing member of MPM BioVentures 2018
GP LLC |
|
10/12/2021 |
**Signature of Reporting
Person |
Date |
iTeos Therapeutics (NASDAQ:ITOS)
Historical Stock Chart
From May 2022 to Jun 2022
iTeos Therapeutics (NASDAQ:ITOS)
Historical Stock Chart
From Jun 2021 to Jun 2022